AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9354211 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tilidine i.v.
Number of subjects: 20
Study 8409145 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric evaluation and outpatient care management program
Number of subjects: 0
Study 8409145 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3535006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 18
Study 3535006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28135225 — intervention group
Group type: EXPERIMENTAL
Intervention: Laddermill (LM) exercise
Number of subjects: 20
Study 28135225 — intervention group
Group type: COMPARATOR
Intervention: Treadmill (TM) exercise
Number of subjects: 20
Study 28005113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet questionnaires
Number of subjects: 483
Study 28005113 — intervention group
Group type: COMPARATOR
Intervention: Paper questionnaires
Number of subjects: 483
Study 25858478 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestyramine 4 g twice daily
Number of subjects: 26
Study 23565660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combined vitamins for 1 year
Number of subjects: 60
Study 23565660 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal vitamin levels
Number of subjects: 60
Study 21639806 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4560
Study 21639806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4560
Study 19210023 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed (subliminal prime to activate common cold schema)
Number of subjects: 0
Study 19210023 — intervention group
Group type: COMPARATOR
Intervention: Control (no subliminal prime)
Number of subjects: 0
Study 17106408 — intervention group
Group type: EXPERIMENTAL
Intervention: Proview pressure phosphene tonometry (PPPT)
Number of subjects: 104
Study 17106408 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometry (GT)
Number of subjects: 104
Study 15231980 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1 and 5 mg/kg on days 2-5)
Number of subjects: 477
Study 15231980 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin estolate (40 mg/kg/day in 3 divided doses for 10 days)
Number of subjects: 477
Study 15231980 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 477
Study 15231980 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 477
Study 11764322 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequency analysis (NF)
Number of subjects: 698
Study 9226734 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 60
Study 9226734 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 60
Study 9226734 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 60
Study 9226734 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 60
Study 9226734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7867225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 16
Study 7867225 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oils
Number of subjects: 16
Study 7867225 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 16
Study 2517679 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (group G)
Number of subjects: 65
Study 2517679 — intervention group
Group type: COMPARATOR
Intervention: Glucose + Intralipid 10% (group GL)
Number of subjects: 65
Study 782956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (HC 17-B)
Number of subjects: 0
Study 782956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 782956 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 0
Study 782956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 21-acetate (HA)
Number of subjects: 0
Study 31202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acoustic radiation force impulse (ARFI) imaging and conventional ultrasound (US)
Number of subjects: 146
Study 31202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasound (US) index (renal length, renal parenchyma thickness and interlobular arterial RI)
Number of subjects: 146
Study 31202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear wave velocity (SWV)
Number of subjects: 146
Study 31202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional US index
Number of subjects: 146
Study 31202455 — intervention group
Group type: COMPARATOR
Intervention: Control group (39 healthy volunteers)
Number of subjects: 146
Study 29033560 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive palliative care in monthly meetings with a specialized palliative care team (SPCT)
Number of subjects: 228
Study 29033560 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228
Study 26149129 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg/day
Number of subjects: 46
Study 26149129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 46
Study 24452168 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR testing with concurrent antistaphylococcal antibiotics
Number of subjects: 0
Study 22952075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 5 mg/day
Number of subjects: 40
Study 22952075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 10 mg/day
Number of subjects: 40
Study 22952075 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 20 mg/day
Number of subjects: 40
Study 22952075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20937929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 27747
Study 20937929 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (CEE plus medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 27747
Study 20937929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27747
Study 18249107 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko technique
Number of subjects: 0
Study 18249107 — intervention group
Group type: COMPARATOR
Intervention: Control group (breathing and relaxation techniques)
Number of subjects: 0
Study 15860686 — intervention group
Group type: EXPERIMENTAL
Intervention: Military anti-shock trouser pants inflation
Number of subjects: 44
Study 14660821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus hydration
Number of subjects: 63
Study 14660821 — intervention group
Group type: COMPARATOR
Intervention: Overnight hydration
Number of subjects: 63
Study 10805061 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 50 mg
Number of subjects: 18
Study 10805061 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg
Number of subjects: 18
Study 10805061 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 150 mg
Number of subjects: 18
Study 9347069 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide
Number of subjects: 0
Study 9347069 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine/creatinine ratio
Number of subjects: 0
Study 7685176 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg captopril twice a day
Number of subjects: 27
Study 7685176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3320747 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive approach
Number of subjects: 57
Study 28222446 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheter removal (Group A)
Number of subjects: 295
Study 28222446 — intervention group
Group type: COMPARATOR
Intervention: Delayed catheter removal (Group B)
Number of subjects: 295
Study 27626622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 100 mg/d for 24 weeks
Number of subjects: 94
Study 27626622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 23992559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-potentiated HUT
Number of subjects: 369
Study 22529363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine enhancement using levodopa
Number of subjects: 0
Study 22529363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20695007 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5mg nightly naltrexone (low-dose naltrexone, LDN)
Number of subjects: 80
Study 19029083 — intervention group
Group type: COMPARATOR
Intervention: 0-50 ng/mL rhVEGF(165) for 7 days in vitro
Number of subjects: 0
Study 19029083 — intervention group
Group type: COMPARATOR
Intervention: 0 or 50 ng/mL rhVEGF(165) for one hour prior to implantation
Number of subjects: 0
Study 16179956 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR pulse sequences; treatment duration: 9 days
Number of subjects: 0
Study 12706694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (3 doses of 25 microg of protein each, with 6 weeks interval and a third dose after 10 months)
Number of subjects: 22
Study 12706694 — intervention group
Group type: COMPARATOR
Intervention: Intranasal vaccination (4 weekly doses followed by a fifth dose after 5 months, each dose consisting of OMVs equivalent to 250 microg of protein)
Number of subjects: 22
Study 10655798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour turning interval
Number of subjects: 26
Study 10655798 — intervention group
Group type: EXPERIMENTAL
Intervention: Core body temperature
Number of subjects: 26
Study 10655798 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin surface temperature
Number of subjects: 26
Study 10655798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral skin surface temperature
Number of subjects: 26
Study 8678499 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg THP vesical irrigation
Number of subjects: 74
Study 8678499 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg THP vesical irrigation
Number of subjects: 74
Study 8479593 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2452505 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral dilation and TUR P
Number of subjects: 317
Study 2452505 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethrotomy according to Otis and TUR P
Number of subjects: 317
Study 2452505 — intervention group
Group type: COMPARATOR
Intervention: TUR P alone
Number of subjects: 317
Study 29507282 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 75
Study 29507282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75
Study 29507282 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 75
Study 29507282 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 29507282 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-remitters
Number of subjects: 75
Study 26442992 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic images with text warnings on cigarette packages
Number of subjects: 2192
Study 26442992 — intervention group
Group type: COMPARATOR
Intervention: Text warnings only
Number of subjects: 2192
Study 26442992 — intervention group
Group type: COMPARATOR
Intervention: Current US Surgeon General's text warnings
Number of subjects: 2192
Study 24019196 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (six 90-min in-person sessions including spiritual component)
Number of subjects: 131
Study 24019196 — intervention group
Group type: COMPARATOR
Intervention: Control group (forms only)
Number of subjects: 131
Study 22681244 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing prophylaxis
Number of subjects: 13
Study 22681244 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylactic dosing regimen
Number of subjects: 13
Study 20447161 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-supported training of the Nasal Airflow Inducing Manoeuvre (NAIM)
Number of subjects: 40
Study 20447161 — intervention group
Group type: COMPARATOR
Intervention: Home practice of the Nasal Airflow Inducing Manoeuvre (NAIM)
Number of subjects: 40
Study 18227328 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency lumbar sympathectomy
Number of subjects: 20
Study 18227328 — intervention group
Group type: COMPARATOR
Intervention: Lumbar sympathetic neurolysis with phenol 7%
Number of subjects: 20
Study 16186372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVI) of 4 mg triamcinolone acetonide (TA)
Number of subjects: 36
Study 16186372 — intervention group
Group type: COMPARATOR
Intervention: Sub-Tenon's infusion (STi) of 40 mg triamcinolone acetonide (TA)
Number of subjects: 36
Study 14578254 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP definition
Number of subjects: 1734
Study 14578254 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 1734
Study 14578254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IGT and NCEP definitions
Number of subjects: 1734
Study 14578254 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP definition with fasting glucose >or=5.4 mmol/l
Number of subjects: 1734
Study 14578254 — intervention group
Group type: COMPARATOR
Intervention: Modified WHO definition
Number of subjects: 1734
Study 10947341 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (bid)
Number of subjects: 722
Study 10947341 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (qid)
Number of subjects: 722
Study 10947341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722
Study 10947341 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (bid and qid)
Number of subjects: 722
Study 8777296 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, amoxycillin, and bismuth)
Number of subjects: 10
Study 8777296 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) administration after Hp eradication
Number of subjects: 10
Study 8777296 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori infection
Number of subjects: 10
Study 1806610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic estrogen‐progestin plus calcium
Number of subjects: 71
Study 1806610 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (calcium carbonate with meals to attain an intake of 1,700 mg daily)
Number of subjects: 71
Study 1806610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 6749443 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Number of subjects: 10
Study 6749443 — intervention group
Group type: COMPARATOR
Intervention: 125 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Number of subjects: 10
Study 31348579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg at 2-week intervals
Number of subjects: 63
Study 28363433 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT) 3×/week for 12 weeks
Number of subjects: 26
Study 28363433 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 26
Study 28363433 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study 26667312 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad film clip
Number of subjects: 178
Study 26667312 — intervention group
Group type: COMPARATOR
Intervention: Neutral film clip
Number of subjects: 178
Study 24124061 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMIER lifestyle intervention
Number of subjects: 501
Study 21863237 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-12 administered at 400 mg/m(2)/day by 72-hour infusion
Number of subjects: 14
Study 19415555 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intolerance of Uncertainty (IU) and High Situational Uncertainty (SU)
Number of subjects: 153
Study 19415555 — intervention group
Group type: COMPARATOR
Intervention: Low Intolerance of Uncertainty (IU) and Low Situational Uncertainty (SU)
Number of subjects: 153
Study 17307180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenic protein (BMP)
Number of subjects: 0
Study 14978184 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-ST
Number of subjects: 430
Study 14978184 — intervention group
Group type: COMPARATOR
Intervention: SRL-CsA-ST
Number of subjects: 430
Study 11230885 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 26 Gy
Number of subjects: 140
Study 11230885 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 40 Gy
Number of subjects: 140
Study 11230885 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 40 Gy for patients in partial response (PR) after CHOP
Number of subjects: 140
Study 9737645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 2700
Study 9737645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 2700
Study 9737645 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 2700
Study 7985630 — intervention group
Group type: EXPERIMENTAL
Intervention: Midluteal phase dietary intake
Number of subjects: 18
Study 2537563 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 253
Study 2537563 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study 1192347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine plus prednisone
Number of subjects: 180
Study 1192347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone
Number of subjects: 180
Study 1192347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine alone
Number of subjects: 180
Study 1192347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone for 4 weeks every 3 months
Number of subjects: 180
Study 1192347 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone plus vincristine for 4 weeks every 3 months
Number of subjects: 180
Study 1192347 — intervention group
Group type: COMPARATOR
Intervention: Vincristine added to prednisone for reinforcement
Number of subjects: 180
Study 30489352 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 11
Study 30489352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29086484 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and internet condition (MIC)
Number of subjects: 59
Study 29086484 — intervention group
Group type: COMPARATOR
Intervention: Nutrition psychoeducation and internet condition (NPC)
Number of subjects: 59
Study 26343603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 23
Study 26343603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23561002 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen (IBUg)
Number of subjects: 50
Study 23561002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAg)
Number of subjects: 50
Study 21525198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin for 8 weeks
Number of subjects: 123
Study 21525198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg riboflavin for 8 weeks
Number of subjects: 123
Study 21525198 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 123
Study 21525198 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 123
Study 18439662 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 27
Study 18439662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17062966 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Group-I; n=40)
Number of subjects: 80
Study 17062966 — intervention group
Group type: COMPARATOR
Intervention: Control (Group-II; n=40)
Number of subjects: 80
Study 12642183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clumsy children
Number of subjects: 10
Study 12642183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 11203855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortify
Number of subjects: 20
Study 11203855 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect‐it!
Number of subjects: 20
Study 11203855 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiguard
Number of subjects: 20
Study 11203855 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no sealing)
Number of subjects: 20
Study 9117838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 144
Study 9117838 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical streptokinase
Number of subjects: 144
Study 9117838 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-streptokinase-treated wounds)
Number of subjects: 144
Study 8478851 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block using steroid/bupivacaine
Number of subjects: 0
Study 3529902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program (3 sessions per week for 8 months)
Number of subjects: 32
Study 3529902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 32
Study 30076327 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive gluteus medius (GM) activity during perturbed walking
Number of subjects: 0
Study 30076327 — intervention group
Group type: EXPERIMENTAL
Intervention: GM activity of the swing leg in response to platform translation late in the gait cycle
Number of subjects: 0
Study 27187267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid outreach suicide preventive intervention (OPAC)
Number of subjects: 133
Study 27187267 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 133